CheckMate 067: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma - European Medical Journal

CheckMate 067: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses CheckMate 067, a randomised, double-blind, phase 3 trial of nivolumab monotherapy or nivolumab combined with ipilimumab versus ipilimumab monotherapy in patients with previously untreated unresectable or metastatic melanoma.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now